This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTLB vs. FEMY, CARA, TENX, LSTA, CCM, CYTH, FBLG, KLTO, GBS, and CRISShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Femasys (FEMY), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Concord Medical Services (CCM), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), GBS (GBS), and Curis (CRIS). These companies are all part of the "medical" sector. XTL Biopharmaceuticals vs. Its Competitors Femasys Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Concord Medical Services Cyclo Therapeutics FibroBiologics Klotho Neurosciences GBS Curis XTL Biopharmaceuticals (NASDAQ:XTLB) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Do insiders and institutionals have more ownership in XTLB or FEMY? 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 11.5% of Femasys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, XTLB or FEMY? XTL Biopharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500. Do analysts recommend XTLB or FEMY? Femasys has a consensus target price of $8.67, suggesting a potential upside of 832.60%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to XTLB or FEMY? In the previous week, Femasys had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Femasys and 1 mentions for XTL Biopharmaceuticals. Femasys' average media sentiment score of 0.92 beat XTL Biopharmaceuticals' score of 0.00 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XTLB or FEMY more profitable? XTL Biopharmaceuticals has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. XTL Biopharmaceuticals' return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets XTL BiopharmaceuticalsN/A N/A N/A Femasys -1,242.06%-392.45%-137.15% Which has preferable valuation & earnings, XTLB or FEMY? XTL Biopharmaceuticals has higher earnings, but lower revenue than Femasys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXTL Biopharmaceuticals$450K16.17-$1.03MN/AN/AFemasys$1.63M14.57-$18.82M-$0.91-1.02 SummaryXTL Biopharmaceuticals and Femasys tied by winning 7 of the 14 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.19M$415.98M$5.45B$8.93BDividend YieldN/A2.45%5.22%4.01%P/E RatioN/A7.2127.2420.06Price / Sales16.173.36426.37117.54Price / CashN/A8.4126.2128.59Price / Book1.340.897.925.56Net Income-$1.03M$10.55M$3.17B$248.56M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.1945 of 5 stars$1.34+18.1%N/AN/A$7.19M$450K0.00N/AFEMYFemasys3.833 of 5 stars$0.97-1.4%$8.67+797.4%-15.9%$25.04M$1.63M-1.0630CARACara Therapeutics0.3412 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2614 of 5 stars$5.76-1.5%$17.50+203.8%+88.0%$24.27MN/A-2.329LSTALisata Therapeutics2.4911 of 5 stars$2.90+3.6%$15.00+417.2%-24.8%$24.12M$1M-1.2630Gap DownCCMConcord Medical Services0.8405 of 5 stars$5.73+4.0%N/A-43.3%$23.92M$52.60M0.00970News CoverageCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.5359 of 5 stars$0.62+0.7%$13.00+1,989.4%-87.0%$23.65MN/A-2.9610Gap UpKLTOKlotho NeurosciencesN/A$1.13+56.9%N/AN/A$23.40MN/A-3.14N/AAnalyst UpgradeGap DownHigh Trading VolumeGBSGBSN/A$1.53-9.5%N/A-2.7%$22.78M$440K-2.737Gap DownCRISCuris2.873 of 5 stars$2.32+6.9%$17.00+632.8%-71.2%$22.70M$10.91M-0.3760High Trading Volume Related Companies and Tools Related Companies Femasys Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Concord Medical Services Competitors Cyclo Therapeutics Competitors FibroBiologics Competitors Klotho Neurosciences Competitors GBS Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts